Clinical Trials Logo

Clinical Trial Summary

The main objective of the study is to assess the efficacy of a home-based, computerized cognitive training (CT) program, called CogmedRM, targeted to improve working memory in children with NF1 and working memory difficulties. This is a Phase II randomized parallel group controlled clinical trial comparing two interventions on cognitive outcomes. Participants will be stratified by stimulant medication use and randomized equally between the two interventions within stratum. Participants will be in the study for to 11 weeks.


Clinical Trial Description

Cognitive deficits are the most important cause of long-term dysfunction in patients with Neurofibromatosis type 1 (NF1). Among the most frequently-occurring difficulties are problems with attention, working memory (WM), and executive functioning (EF). Remediation and interventions to improve those deficits have the potential to impact the quality of life and long-term prognosis in this population. Cognitive training (CT) programs have increasingly been used independently or in conjunction with pharmacotherapies in children with accidental or disease-related brain injury. CogmedRM is both the most well-researched and widely-used CT program for remediation of WM deficits. Results from numerous randomized, controlled trials conducted with a variety of pediatric and adult patient populations generally show that CogmedRM training is associated with robust gains in performance-based WM scores over the short term, with some variability in improvement across disease groups. A single arm pilot study of CogmedRM in a sample of children with NF1 conducted at Children's National Medical Center has shown that the approach is likely feasible and acceptable to families. Because many children with NF1 are treated with stimulant medications, and there is biological evidence that both CT and Methylphenidate act on dopaminergic systems, the investigators are also interested in examining whether or not there is a synergistic effect between these widely available and safe interventions. Thus, the aim is to assess the efficacy of a home-based, computerized cognitive training (CT) program in a sample of 90 children aged 8-16 with NF1 and working memory difficulties. This study will be conducted over the span of four years. If the participant qualifies following baseline testing, he/she will be randomized to the intervention, CogmedRM, or the active control condition, MobyMax (an online reading program). The participant will have 5-9 weeks to complete the program and will have follow-up testing 2 weeks after finishing the program. If CT, either singly or in combination with stimulant medication, can be shown to be efficacious in a sample of NF1 pediatric patients at high risk for neurocognitive deficits, this intervention plan could be rapidly translated to clinical practice. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02944032
Study type Interventional
Source Children's National Research Institute
Contact
Status Completed
Phase N/A
Start date May 2016
Completion date September 27, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03190915 - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Phase 2
Recruiting NCT03326388 - Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Phase 1/Phase 2
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Active, not recruiting NCT01362803 - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Phase 1/Phase 2
Active, not recruiting NCT01218139 - Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients N/A
Recruiting NCT05149469 - Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
Not yet recruiting NCT02505412 - Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients N/A
Terminated NCT02256124 - Effect of Lamotrigine on Cognition in NF1 Phase 2/Phase 3
Completed NCT01707836 - Neurofibromatosis Type 1 Brain Tumor Genetic Risk N/A
Active, not recruiting NCT01218152 - Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs N/A
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Recruiting NCT05186870 - Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
Active, not recruiting NCT03231306 - Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Phase 2
Withdrawn NCT03332030 - Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Recruiting NCT02964884 - Interventions for Reading Disabilities in NF1 Phase 2
Recruiting NCT05388370 - PASS of Paediatric Patients Initiating Selumetinib
Recruiting NCT02777775 - Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. N/A
Completed NCT01851135 - Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 N/A
Completed NCT01410006 - Neurofibromatosis Type 1 Patient Registry N/A
Active, not recruiting NCT00326872 - AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine Phase 2